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OBJECTIVES: To determine the cost-effectiveness relation of adding Saxagliptin to
Metformin therapy (SAXAMET) compared to adding Sulfonylureas (SULFMET),
in patientswith type 2 diabetesmellitus (DM2)whohave failed to achieve adequate
glycemic control with metformin. METHODS: A discrete event simulation model
(Cardiff long term cost-utilitymodel) with a fixed time increase based on UKPDS 68
was used to simulate disease progression and to obtain an estimate of the treat-
ment’s economic and health consequences in DM2 patients. Clinical efficacy pa-
rameters for Saxagliptin were obtained from the literature; drug acquisition costs,
adverse events (AEs) and microvascular and macrovascular complications were
taken into account. The time horizon was 20 years and the perspective was that of
the public health care system in Chile. Costs were expressed in US dollars (2009),
with an annual 3.5% discount. RESULTS: A lower number of non-fatal events were
found for the SAXAMET-treated group versus the SULFMET-treated group. Ad-
ditionally, the model predicted a lower number of fatal macrovascular (132.3 vs.
136.0) andmicrovascular (19.6 vs. 19.7) events for the SAXAMET-treated group vs.
the SULFMET-treated group. The total cost of the SAXAMET cohort was lower
than the SULFMET cohort: US$ 15.006.011 andU$S 14.557.581, respectively. Treat-
ment with SAXAMET resulted in a higher number of QALYs (9,794 vs. 9,594) and
LYs (23,068 vs. 23,019) for the 1000 patients’ cohort than treatmentwith SULFMET;
the incremental analysis per QALY and LY gained was -US$2,243 and US$ 9,182
respectively (dominant). CONCLUSIONS: Results suggest that the addition of Saxa-
gliptin to metformin therapy is dominant compared to the addition of sulfonyl-
ureas; therefore, this intervention would represent an efficient use of health re-
sources for DM2 patients in Chile.
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OBJECTIVES: The objective was to determine whether the use of insulin glargine
(IG, Lantus) could result in cost savings in comparison with insulin detemir (ID,
Levemir) in T2D patients in the UK. METHODS: Clinical data for the analysis was
taken from a 1 year multi-national study (Rosenstock 2008) in 582 insulin-naïve
patients treated with IG or ID as add-on therapy to oral glucose lowering drugs. IG
was administered once daily in linewith it’s licence and ID once (44% of patients) or
twice daily (55%) according to treatment response. Mean daily insulin doses were
40U for IG and 71U for ID. Baseline characteristics were comparable on study entry.
After 1 year glycaemic control, weight gain, adverse events and risk of hypoglycae-
mia were similar for both groups so a cost minimisation analysis was undertaken.
Costs were calculated from a UK NHS perspective using MIMS November 2010
prices. Insulin cost was based on IG SoloStar and ID FlexPen prefilled disposable
injection devices, which are of similar cost. It was assumed that a new needle,
lancet and blood glucose test strip were used for each injection with a 2U priming
dose of insulin before each injection. RESULTS: The annual cost per patient for
needleswas £43 for IG and £66 for ID. The cost of lancets and test stripswas £122 for
IG and £190 for ID. The annual cost of insulin was £426 for IG and £758 for ID. The
total annual cost per patient of administering IGwas £591 comparedwith £1014 for
ID. Sensitivity analyses for weight gain, IG device and insulin dose confirmed the
robustness of the base case results. CONCLUSIONS: IG may represent a more cost
effective option for T2D patients in theUK requiring basal insulin analogue therapy
with potential annual cost savings of 42% (£423/patient) compared with ID.
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OBJECTIVES: Hypoglycemia is a common treatment related side effect of diabetes,
which can be associated with frequent emergency room use and hospitalization.
The objective of this study was to assess the direct medical costs of individual
hypoglycemia events in a US population of type 2 diabetes. METHODS: Patients
18 years with type 2 diabetes diagnosed during the period 2003 to 2008 were
selected from the MarketScan® Research Databases and followed from their first
diabetes diagnosis in the study period until the end of continuous coverage or
December 31, 2008, whichever came first. All individual hypoglycemia events iden-
tified by a claim (ICD-9-CM 250.3, 250.8, 251.0, 251.1, 251.2) on a unique date were
counted for each patient. Direct medical costs were calculated per hypoglycemia
event by treatment setting and diabetes drug regimen. RESULTS: A total of 2.4
million diabetes patients were selected. During follow-up, 91,595 of these patients
experienced 169,248 hypoglycemia events. Costs were highest for hypoglycemia
events identified in the emergency room (ER)-to-inpatient setting ($10,362/event),
followed by inpatient ($7,317/event), ER ($701/event), and outpatient ($285/event)
settings. Patients treated with an insulin only regimen had the highest direct med-
ical costs of hypoglycemia ($9.49 per patient per month). Among patients treated
with non-insulin regimens, the estimated hypoglycemia costs for patients on sul-
fonylureas were $3.87 per patient per month and $0.84 for other OADs.
CONCLUSIONS: Direct medical costs associated with hypoglycemia among type 2
diabetes patients varied by treatment setting and drug regimen. Patients treated
with insulin had the highest direct medical costs. Within non-insulin regimens,
patients on sulfonylureas had higher costs than those on non-sulfonylurea OADs.
Treatment strategies that provide effective glycemic control, with a lower potential
for inducing hypoglycemia should be considered in the management of type 2
diabetes.
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OBJECTIVES: The study assessed the economic burden incurred by type 2 diabetes
mellitus (T2DM) patients with oral anti-diabetic drugs (OADs) therapy in China.
METHODS: A cross-sectional survey was conducted between Dec 3rd, 2008 and July
31st, 2009 at 75 urban hospitals in 9 cities in China. A total of 9577 T2DM patients
with OADs therapy completed the self-administered questionnaires during their
clinical visits. The information collected from questionnaire included demo-
graphic characteristics, utilization of OADs, glycemic control, diabetes complica-
tions, annual direct medical costs and productivity lost associated with T2DM.
RESULTS:Themean age (SD)was 59.512.7 years, 51.1%weremale and themean
diabetes duration (SD) was 7.96.3 years. Only 7.9% and 15.3% of the patients
achieved HbA1c6.5%, and HbA1c7.0% respectively. The average total medical
expenditures was CNY 9127.2 per year, of which CNY 6478.5 was spent on T2DM.
The annual expenditure of OADs was CNY 4279.4, accounting for 66.1% of the total
annual T2DM treatment expenditure. The annual average diabetes-related costs
for outpatient and hospitalization were CNY 5998.9 and 4265.8 respectively. T2DM
patients diagnosed less than 3 years, 3-5 years, 5-10 years and more than 10 years
had an annual average treatment cost of CNY 4783.0, 5829.5, 6248.4, and 8183.8
respectively. The average annual productivity lost due to T2DM was 29.9 working
days. It resulted in an estimated average opportunity cost of CNY 2367.1 per capita
(The 2008 average annual income of urban residents was CNY 28898). The direct
treatment cost of T2DM and opportunity cost together accounted for 56% of pa-
tients’ disposable income in 2008 (CNY 15781). CONCLUSIONS: The study demon-
strated the high economic burden and inadequate glucose control among T2DM
patients with OADs therapy. The direct medical cost of T2DM increases with dis-
ease progression. It highlights the importance of implementing cost-effective ther-
apeutic regimens to improve diabetes management.
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OBJECTIVES: (1) To identify and analyse the benefits and costs of sponsored clinical
trials in a publicly funded New Zealand hospital, from the perspective of (a) the
research unit and (b) the district health board; (2) To identify patterns of costs and
benefits during the pre-trial, trial and follow-up stages of a clinical trial.METHODS:
We draw on the data relating to cases and controls in a health outcomes study of
two phase III clinical trials to assess preventative medication for patients at risk of
serious cardiovascular events. The data includeMinistry of Health data, The Centre
for Clinical Research and Effective Practice (CCRep) profit and loss statements,
CountiesManukauDistrict Health Board (CMDHB) Chronic CareManagement data,
trial protocols and data from a trial health outcome co-study. We identify patterns
of costs and benefits during the enrolment, trial and follow-up stages of a clinical
trial. RESULTS: The research unit and the health board both derive economic ben-
efits from these trials. The magnitude of the benefits differs depending on the
perspective taken. The research unit has total economic benefits ranging from
US$470 and US$846 per participant which it is able to reinvest into other research
projects. We find the benefits from the perspective of the health board are positive
but small US $15 - $45 per participant over the eight year period. Savings from
treatment cost avoidance are lower than anticipated. We find two periods where
costs are highest (1) during enrolment and (2) at the end of the trial.CONCLUSIONS:
There may be economic advantages in actively encouraging sponsored clinical
trials within New Zealand publically funded hospitals. This study provides evi-
dence of differing patterns of costs and benefits during the three stages of a clinical
trial – enrolment, trial and follow-up.
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OBJECTIVES: Diabetic macular edema (DME) is an ophthalmologic complication
that develops in a subset of patients with diabetic retinopathy and that causes loss
of functionality, reduced health-related quality of life, visual impairment, and if
left untreated, blindness. A cost-effectiveness analysis was conducted to measure
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